Study of RP-6306 With Gemcitabine in Advanced Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

December 16, 2021

Primary Completion Date

August 28, 2024

Study Completion Date

August 28, 2024

Conditions
Adult Solid Tumor
Interventions
DRUG

RP-6306 (oral PKMYT1 inhibitor)

RP-6306 in combination with gemcitabine

Trial Locations (11)

10032

# 1008, Columbia University, New York

10065

# 1004, Memorial Sloan Kettering Cancer Institute, New York

19104

# 1010, University of Pennsylvania, Philadelphia

32224

# 1017, Mayo Clinic, Jacksonville

33612

# 1022, Moffitt Cancer Center, Tampa

49546

# 1023, START Midwest, Grand Rapids

55902

# 1016, Mayo Clinic, Rochester

85054

# 1018, Mayo Clinic, Phoenix

90095

# 1019, UCLA, Westwood Cancer Center, Los Angeles

M5G 2C1

# 2001, Princess Margaret Cancer Centre, Toronto

Unknown

# 3003, Sarah Cannon Research Institute, London

Sponsors
All Listed Sponsors
lead

Repare Therapeutics

INDUSTRY

NCT05147272 - Study of RP-6306 With Gemcitabine in Advanced Solid Tumors | Biotech Hunter | Biotech Hunter